ArticleNanomaterials (Basel, Switzerland)2022
MOF-Derived Cu@N-C Catalyst for 1,3-Dipolar Cycloaddition Reaction.
Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Development of Noval, Recyclable, and Tunable Aryl Imidazolium Salts with a Dual Brønsted-Lewis Acid Character as Catalysts for the Copper(I)-Catalyzed Azide-Alkyne Cycloaddition Reaction (CuAAC).ACS organic & inorganic Au · 2026Article
- Copper immobilized MIL-125-NHScientific reports · 2025Article
- Recent advances in magnetic nanocatalysts for synthesis of imidazo[1,2-RSC advances · 2025Review
- Lead free perovskite integrated metal organic framework as heterogeneous catalyst for efficient three component click reaction.Scientific reports · 2025Article
- Post-synthetic modification of Zr-based metal organic framework by schiff base zinc complex for catalytic applications in a click reaction.Scientific reports · 2024Article
- New Insights intoNanomaterials (Basel, Switzerland) · 2023Review
- Synthesis and Antimicrobial Activity of the PathogenicInternational journal of molecular sciences · 2023Article
- Versatile Synthetic Platform for 1,2,3-Triazole Chemistry.ACS omega · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cu(im)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.